Showing results (181-190 of 456) with videos related to

Sort By:
Pageof 46
Urologic Oncology|January 13, 2011
Neoadjuvant M-VAC (methotrexate, vinblastine, adriamycin, and cisplatin) chemotherapy and bladder preservation for muscle-infiltrating transitional cell carcinoma of the bladderC N Sternberg, V Pansadoro, S Lauretti, et al.
European Urology Focus|June 14, 2024
Artificial INtelligence to Support Informed DEcision-making (INSIDE) for Improved Literature Analysis in OncologyArnulf Stenzl, Andrew J Armstrong, Andrea Sboner, et al.
Cancer|April 28, 2009
Gemcitabine and paclitaxel every 2 weeks in patients with previously untreated urothelial carcinomaFabio Calabrò, Vito Lorusso, Gerardo Rosati, et al.
Cancer Treatment Reviews|April 11, 2021
Avelumab first-line maintenance in locally advanced or metastatic urothelial carcinoma: Applying clinical trial findings to clinical practicePetros Grivas, Neeraj Agarwal, Sumanta Pal, et al.
The Journal of Allergy and Clinical Immunology|April 1, 1989
Hypereosinophilia, neurologic, and gastrointestinal symptoms after bee-pollen ingestionF L Lin, T R Vaughan, M L Vandewalker, et al.
Phytotherapy Research : PTR|January 15, 2009
Antioxidant, antioedema and analgesic activities of Andrographis paniculata extracts and their active constituent andrographolideF L Lin, S J Wu, S C Lee, et al.
Cancer|September 15, 1993
Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin, and cisplatin) for infiltrating transitional cell carcinoma of the bladderC N Sternberg, M G Arena, F Calabresi, et al.
Future Oncology (London, England)|June 3, 2022
Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trialMatthew R Smith, Maha Hussain, Fred Saad, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 29, 1994
Preparation and screening of an arrayed human genomic library generated with the P1 cloning systemN S Shepherd, B D Pfrogner, J N Coulby, et al.
The Lancet. Oncology|August 9, 2014
Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trialKarim Fizazi, Howard I Scher, Kurt Miller, et al.
Pageof 46